Characterization of antibodies to CA 125 that bind preferentially to the cell-associated form of the antigen

Tumor Biology

Volumn 27, Issue 3, 2006, Pages 122-132

  Singleton, Judith ^a   Guillen, Darlene E ^a   Scully, Michael S ^a   Xue, Jiyan ^a   Moffet, Jennifer ^a   Chen, Chaoyuan ^a   Patel, Sima R ^a   Schilling, Adriane ^a   Corisdeo, Susanne ^a   Yang, Qifeng ^a   Wang, Baiyang ^a   Soltis, Daniel A ^a   Albone, Earl F ^a,b  

^a PURDUE PHARMA L P   (United States)

^b BioRexis Pharmaceutical Corporation   (United States)

Author keywords

C terminal repeat domain; Ca 125; Shed antigen

Indexed keywords

CA 125 ANTIGEN; CELL ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; BINDING COMPETITION; BINDING SITE; CANCER RELAPSE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 33646486097     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092717     Document Type: Article

References (32)

1. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 1983;309:883-887.
2. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K: The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol 2002;23:154-169.
3. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol 2001;22:348-366.
4. Yin BW, Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276:27371-27375.
5. Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I: Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer 2002;12:372-375.
6. Leake J, Woolas RP, Daniel J, Oram DH, Brown CL: Immunocytochemical and serological expression of CA 125: a clinicopathological study of 40 malignant ovarian epithelial tumours. Histopathology 1994;24:57-64.
7. Loy TS, Quesenberry JT, Sharp SC: Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol 1992;98:175-179.
8. Nap M, Vitali A, Nustad K, Bast RC Jr, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Bormer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarstrom S, Kenemans P, Hilgers J: Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumor Biol 1996;17:325-331.
9. Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ: Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene 2003;22:7225-7232.
10. Beck EP, Moldenhauer A, Merkle E, Kiesewetter F, Jager W, Wildt L, Lang N: CA 125 production and release by ovarian cancer cells in vitro. Int J Biol Markers 1998;13:200-206.
11. Duffy MJ: Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001;38: 225-262.
12. Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21(suppl 6):251S-272S.
13. Lastoria S, Panza N, Esposito G, Vergara E, Castelli L, Caraco C, Battista C, Pacilio G. Salvatore M: Management of patients with ovarian cancer using monoclonal antibodies. Biomed Pharmacother 1992;46:453-463.
14. Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O: Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril 1993;59:1028-1035.
15. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-1551.
16. Nustad K, Bast RC Jr, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Bormer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarstrom S, Kenemans P, Hilgers J: Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumor Biol 1996;17: 196-219.
17. Mahe MA, Fumoleau P, Fabbro M, Guastalla JP, Faurous P, Chauvot P, Chetanoud L, Classe JM, Rouanet P, Chatal JF: A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 1999;5:3249s-3253s.
18. Nesselhut T: Influence of MAb (F(Ab)2 OC 125 on the survival rate of ovarian carcinoma patients. Hybridoma 1993;12:567-570.
19. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-3516.
20. Davies Q, Perkins AC, Frier M, Watson S, Lalani E, Symonds EM: The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur J Nucl Med 1997;24:206-209.
21. Haisma HJ, Battaile A, Stradtman EW, Knapp RC, Zurawski VR Jr: Antibody-antigen complex formation following injection of OC125 monoclonal antibody in patients with ovarian cancer. Int J Cancer 1987;40:758-762.
22. Pimm MV, Durrant LG, Baldwin RW: Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model. Eur J Cancer Clin Oncol 1989;25:1325-1332.
23. Zalutsky MR, Knapp RC, Bast RC Jr: Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Int J Rad Appl Instrum B 1988;15:431-437.
24. Sambrook J, Russel D (eds): Molecular Cloning: A Laboratory Manual, ed 3. New York, Cold Spring Harbor Laboratory Press, 2001.
25. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, McIntyre GD: Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 1997;16:381-389.
26. Ho JJ, Jaituni RS, Crawley SC, Yang SC, Gum JR, Kim YS: N-glycosylation is required for the surface localization of MUC17 mucin. Int J Oncol 2003;23:585-592.
27. Komatsu M, Arango ME, Carraway KL: Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis. Biochem J 2002;368:41-48.
28. Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A: Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun 2001;283:715-720.
29. Harlozinska A, Sedlaczek P, Van Dalen A, Rozdolski K, Einarsson R: TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. Anticancer Res 1997;17:4473-4478.
30. Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC Jr: CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 1990;36:161-165.
31. Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, Erten O: Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002;85:108-113.
32. Berger MA, Masters G, Singleton J, Scully MS, Grimm LG, Soltis DA, Albone EF: Pharmacokinetics, biodistribution, and radioimmunotherapy with 776.1 in a murine model of human ovarian cancer. Cancer Biother Radiopharm 2005, in press.